---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-011167"
form_type: "8-K"
ticker: "RCEL"
cik: "0001762303"
company_name: "AVITA Medical, Inc."
filed_at: "2026-01-13T23:59:59+00:00"
generated_at: "2026-05-16T10:41:39.651766+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AVITA Medical: Q4 rev ~$17.6M, FY2025 $71.6M; new $60M credit facility; FY2026 guidance $80-85M

## Summary
- Q4 2025 revenue ~$17.6M (vs $18.4M Q4 2024); Cohealyx-I fully enrolled, PermeaDerm-I >75% enrolled in Dec 2025.
- FY2025 revenue $71.6M, up 11% YoY from $64.3M in 2024, within revised guidance.
- FY2026 revenue guidance $80-85M (12-19% growth); TTM revenue covenant $68.5M for Q1 2026, $73M for FY2026.
- New $60M credit facility with Perceptive Advisors ($50M funded, $10M option until Q1 2027); SOFR+7.5% (4% floor).
- Warrant to purchase 500k shares (additional 150k if $10M drawn) at VWAP-based price; 10-year term; registration rights.

## SEC filing metadata
- accession: 0001193125-26-011167
- form_type: 8-K
- ticker: RCEL
- cik: 0001762303
- company_name: AVITA Medical, Inc.
- filed_at: 2026-01-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 1.02, 2.02, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1762303/000119312526011167/0001193125-26-011167-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1762303/000119312526011167/rcel-20260113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-011167
- JSON: https://secwatch.observer/filing/0001193125-26-011167.json
- Plain text: https://secwatch.observer/filing/0001193125-26-011167.txt

## Key facts
- Debt Financings
  AVITA Medical, Inc. incurred credit facility of up to $60 million with Perceptive Credit Holdings V, LP at greater of (x) the SOFR rate for such period and (y) 4.00% plus, in either case, maturing five-year senior secured credit facility.
  - Instrument: credit facility
  - Principal: up to $60 million
  - Counterparty: Perceptive Credit Holdings V, LP
  - Rate: greater of (x) the SOFR rate for such period and (y) 4.00% plus, in either case,
  - Maturity: five-year senior secured credit facility
  - Event: incurrence
  source text: Credit Agreement provides for a five-year senior secured credit facility in an aggregate principal amount of up to $60 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1762303/000119312526011167/0001193125-26-011167-index.htm
- Material Agreements
  AVITA Medical, Inc. entered into Credit Agreement and Guaranty with Perceptive Credit Holdings V, LP valued at $60 million (effective 2026-01-13).
  - Action: entry
  - Agreement: credit facility
  - Counterparty: Perceptive Credit Holdings V, LP
  - Value: $60 million
  - Effective: 2026-01-13
  source text: On January 13, 2026 (the “Closing Date”), AVITA Medical, Inc. (the “Company”) entered into a Credit Agreement and Guaranty (the “Credit Agreement”) and a Security Agreement (the “Security Agreement”), by and among the Company, as borrower, Avita Medical Americas, LLC, a wholly-owned subsidiary of the Company, as guarantor (the “Guarantor,” taken together with the Company, the “Obligors”) and Perceptive Credit Holdings V, LP as a lender and the administrative agent (the “Lender,” and the “Administrative Agent,” as applicable).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1762303/000119312526011167/0001193125-26-011167-index.htm
- Material Agreements
  AVITA Medical, Inc. terminated Existing Credit Agreement with Lender under existing facility (effective 2026-01-13).
  - Action: termination
  - Agreement: credit facility
  - Counterparty: Lender under existing facility
  - Effective: 2026-01-13
  source text: Simultaneously with the closing of the Initial Commitment Amount, the Company repaid in full and terminated all of its obligations and commitments (the “Refinancing Transaction”) under the Existing Credit Agreement (as defined below).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1762303/000119312526011167/0001193125-26-011167-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.